Want to see SE:IVACC full AI Analyst Report?
IVACC Stock Chart & Stats
kr0.92
-kr0.06(-5.24%)
At close: 4:00 PM EST
kr0.92
-kr0.06(-5.24%)
Day’s Range― - ―
52-Week Rangekr0.57 - kr1.46
Previous CloseN/A
Volume791.15K
Average Volume (3M)373.34K
Market Cap
kr445.78M
Enterprise Valuekr301.20M
Total Cash (Recent Filing)kr145.63M
Total Debt (Recent Filing)kr357.00K
Price to Earnings (P/E)―
Beta0.58
Next Earnings
Aug 20, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding340,813,200
10 Day Avg. Volume453,808
30 Day Avg. Volume373,337
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.00
Price to Sales (P/S)13.68
P/FCF Ratio-4.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.22
Revenue Forecast (FY)kr16.00M
Bulls Say, Bears Say
Bulls Say
Low Leverage And Substantial EquityMinimal debt and a large equity base (253.2M TTM) provide durable financial flexibility. This cushion reduces near-term refinancing risk, supports continued R&D and commercialization spending, and preserves strategic optionality for partnerships or licensing over the coming months.
Improving Free Cash Flow TrendA ~48% improvement in free cash flow, despite remaining negative, signals improving cash conversion and operational efficiency. This positive trajectory can extend runway, lower near-term financing pressure, and reflects management progress on cost control or revenue execution over a medium-term horizon.
Commercialized Vaccine With Partner DistributionOwning a commercial product (Strangvac) and established distribution/partner channels creates recurring revenue capability and validated market fit in equine health. Partner-led commercialization enables geographic scale and reduces the binary risk of pre-commercial programs over the next several months.
Bears Say
Persistent Heavy Cash BurnVery large negative operating cash flow and FCF indicate the company is consuming capital rapidly. Without meaningful revenue growth or new financing, this burn will deplete reserves, likely forcing dilutive capital raises or cuts to R&D and commercialization investments within months.
Deep Operating Losses And Negative Gross ProfitNegative gross profit and extreme operating/net margins show current unit economics are destroying value. Such structural loss-making implies revenue increases alone may not restore profitability without significant cost structure changes or price/mix improvements, threatening long-term sustainability.
Revenue Modest, Single-product ConcentrationModest, declining revenue concentrated in one product and partner-driven channels increases vulnerability to adoption cycles, partner terms, or competitive shifts. Limited diversification slows path to self-funding and raises execution risk if Strangvac traction stalls or margins compress.
Intervacc AB News
IVACC FAQ
What was Intervacc AB’s price range in the past 12 months?
Intervacc AB lowest stock price was kr0.57 and its highest was kr1.46 in the past 12 months.
What is Intervacc AB’s market cap?
Intervacc AB’s market cap is kr445.78M.
When is Intervacc AB’s upcoming earnings report date?
Intervacc AB’s upcoming earnings report date is Aug 20, 2026 which is in 48 days.
How were Intervacc AB’s earnings last quarter?
Intervacc AB released its earnings results on May 13, 2026. The company reported -kr0.06 earnings per share for the quarter, the consensus estimate of -kr0.06 by kr0.
Is Intervacc AB overvalued?
According to Wall Street analysts Intervacc AB’s price is currently Overvalued.
Does Intervacc AB pay dividends?
Intervacc AB does not currently pay dividends.
What is Intervacc AB’s EPS estimate?
Intervacc AB’s EPS estimate is -0.05.
How many shares outstanding does Intervacc AB have?
Intervacc AB has 340,813,200 shares outstanding.
What happened to Intervacc AB’s price movement after its last earnings report?
Intervacc AB reported an EPS of -kr0.06 in its last earnings report, expectations of -kr0.06. Following the earnings report the stock price went down -14.82%.
Which hedge fund is a major shareholder of Intervacc AB?
Currently, no hedge funds are holding shares in SE:IVACC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Intervacc AB
Intervacc AB (publ) is a Swedish biotechnology company primarily engaged in the research and development of innovative vaccines designed to combat bacterial infections in animal health. The firm's vaccine pipeline targets various animals, including horses, piglets, and dairy cows, with its key product, Strangvac, specifically developed to prevent equine strangles. Beyond its current offerings, Intervacc is also advancing vaccines against Streptococcus suis and Staphylococcus aureus infections. In addition to vaccine development, the company distributes veterinary medicines and provides essential diagnostic services in veterinary bacteriology to clinics and stud farms. Headquartered in Hägersten, Sweden, Intervacc serves customers across the Nordic countries and the Baltic states.
Technical Analysis
Xbrane Biopharma AB
―
Elicera Therapeutics AB
―
Ascelia Pharma AB
―
IRLAB Therapeutics AB Class A
―
Immunicum AB
―